Literature DB >> 29113910

The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease.

Marie Boyle1, Steven Masson1, Quentin M Anstee2.   

Abstract

Current medical practice artificially dichotomises a diagnosis of fatty liver disease into one of two common forms: alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). Together, these account for the majority of chronic liver diseases worldwide. In recent years, there has been a dramatic increase in the prevalence of obesity and metabolic syndrome within the general population. These factors now coexist with alcohol consumption in a substantial proportion of the population. Each exposure sensitises the liver to the injurious effects of the other; an interaction that drives and potentially accelerates the genesis of liver disease. We review the epidemiological evidence and scientific literature that considers how alcohol consumption interacts with components of the metabolic syndrome to exert synergistic or supra-additive effects on the development and progression of liver disease, before discussing how these interactions may be addressed in clinical practice.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALD; Alcohol; Liver; NAFLD; Pathogenesis

Mesh:

Year:  2017        PMID: 29113910     DOI: 10.1016/j.jhep.2017.11.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  33 in total

Review 1.  Alcoholic liver disease.

Authors:  Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto
Journal:  Nat Rev Dis Primers       Date:  2018-08-16       Impact factor: 52.329

2.  Integrated Care of Alcohol-Related Liver Disease.

Authors:  Gerald S Winder; Anne C Fernandez; Jessica L Mellinger
Journal:  J Clin Exp Hepatol       Date:  2022-01-31

Review 3.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 4.  Current Medical Treatment for Alcohol-Associated Liver Disease.

Authors:  Gustavo Ayares; Francisco Idalsoaga; Luis A Díaz; Jorge Arnold; Juan P Arab
Journal:  J Clin Exp Hepatol       Date:  2022-02-12

Review 5.  Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis.

Authors:  Srikanta Dash; Yucel Aydin; Tong Wu
Journal:  Semin Cell Dev Biol       Date:  2019-08-08       Impact factor: 7.727

Review 6.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

7.  Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Shang-Chin Huang; Hau-Jyun Su; Jia-Horng Kao; Tai-Chung Tseng; Hung-Chih Yang; Tung-Hung Su; Pei-Jer Chen; Chun-Jen Liu
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

Review 8.  The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome.

Authors:  Stephen Malnick; Yaakov Maor
Journal:  Visc Med       Date:  2020-04-23

9.  Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Gian Paolo Caviglia; Angelo Armandi; Chiara Rosso; Silvia Gaia; Serena Aneli; Emanuela Rolle; Maria Lorena Abate; Antonella Olivero; Aurora Nicolosi; Marta Guariglia; Davide Giuseppe Ribaldone; Patrizia Carucci; Giorgio Maria Saracco; Elisabetta Bugianesi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

Review 10.  Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?

Authors:  Shaheen Tomah; Naim Alkhouri; Osama Hamdy
Journal:  Clin Diabetes Endocrinol       Date:  2020-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.